The FDA issued a proposed rule adding six bulk drug substances to the list of materials that can be used in compounding, while removing four substances.
In addition, the agency is proposing to use a new set of four criteria when evaluating substances for inclusion. The FDA will consider each criterion on a substance-by-substance basis, including:
- The physical and chemical characterizations of the substance,
- Any safety issues raised in using the substance in compounded drug products,
- The available evidence of effectiveness or lack of effectiveness of a drug product compounded with the substance, if any such evidence exists, and
- Historical use of the substance in compounded drug products, including information about the medical conditions the substance has been used to treat, and any references in peer-reviewed medical literature.